Alnylam Pharmaceuticals
Edit Page
Report
Scan day: 04 March 2014 UTC
19
Virus safety - good
Description: Develops novel therapeutics based RNAi. Provides overview of recent drug development programs. Includes company profile and technology information.
Alnylam is developing an entirely new class of medicines based on the breakthrough discovery in biology known as RNA interference, or RNAi. Alnylam believes that RNAi therapeutics are a promising approach to silence disease-causing genes, and represent an opportunity to transform the treatment of many diseases.
Size: 312 chars
Contact Information
Email: —
Phone&Fax: —
Address: —
Extended: —
WEBSITE Info
| Page title: | Alnylam |
| Keywords: | |
| Description: | |
| IP-address: | 216.92.19.121 |
WHOIS Info
| NS | Name Server: DNS1.EASYDNS.COM Name Server: DNS2.EASYDNS.NET |
| WHOIS | Status: clientTransferProhibited |
| Date | Creation Date: 26-jun-2002 Expiration Date: 26-jun-2015 |